Document:

EX-10.8

 Exhibit 10.8 
  

 
 Patent and Know How License
Agreement 
  
  

between 
 Kimberly-Clark Worldwide, Inc. 
 and 

Avent, Inc. 
 Made as of
the     day of             , 2014 

 PATENT AND KNOW HOW LICENSE AGREEMENT 

THIS AGREEMENT, effective as of the     day of             ,
2014, by and between KIMBERLY-CLARK WORLDWIDE, INC., a Delaware corporation (“KCWW” or “Licensor”), and AVENT, INC., a Delaware corporation (“Avent” or “Licensee”). 

W I T N E S S E T H: 

WHEREAS, Kimberly-Clark Corporation (“Kimberly-Clark”), the sole shareholder of KCWW, is contributing its Health Care business to
Halyard Health, Inc. (“Halyard”), the sole shareholder of Avent, as of             , 2014, and is then distributing to the shareholders of Kimberly-Clark all of the shares of
common stock of Halyard on a pro-rata basis; and 
 WHEREAS, KCWW possesses valuable patents and technology relating to products
manufactured and marketed by Avent and its affiliates; and 
 WHEREAS, in connection with the contribution, KCWW is assigning to Avent
certain of KCWW’s patents and know how and granting licenses to Avent under certain of KCWW’s patents and know how, in both cases relating to certain products manufactured and marketed by Avent and its affiliates; and 

WHEREAS, also in connection with the contribution, Avent is granting back to KCWW licenses under certain of the patents and technology
assigned to Avent as they relate to certain products manufactured and marketed by KCWW and its affiliates; and 
 WHEREAS, KCWW and Avent
desire to enter into this agreement to define the terms and conditions of the licenses set forth herein. 
 NOW, THEREFORE, in consideration
of the mutual covenants contained herein, the parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 The
following terms shall have the meanings hereinafter set forth. Capitalized terms used but not otherwise defined elsewhere in this Agreement shall have the respective meanings given to such terms in the Distribution Agreement. Unless the context
clearly requires otherwise, the singular shall have the same meaning as the plural and vice versa: 
 1.01 Affiliates - Means, with
respect to any Person, any other Person that directly or indirectly controls, is controlled by or is under common control with such Person. For the purpose of this definition, the term “control” means the power to direct the management of
an entity, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the term “controlled” has the meaning correlative to the foregoing. After the Distribution, Halyard and Kimberly-Clark
shall not be deemed to be under common control for purposes hereof due solely to the fact that 

  
 Page 1 

 
Halyard and Kimberly-Clark have common stockholders. Notwithstanding the foregoing definition, Hogla-Kimberly, Kimberly-Clark de Mexico, Kimberly-Clark Lever Private Limited and Olayan
Kimberly-Clark are Affiliates of Kimberly-Clark. 
 1.02 Confidential Information - Any and all proprietary information without
regard to form, both technical and business related, including Know How (as defined hereinafter), financial data, financial plans, product or service plans or lists of actual or potential customers or suppliers which is not commonly known by or
available to the public. 
 1.03 Consumer Market – End users that are directly purchasing or otherwise obtaining Consumer
Products for consumption or customers who are retail or other outlets that resell Consumer Products to the end user for consumption. Notwithstanding anything to the contrary in this Agreement, Kimberly-Clark and its Affiliates may continue selling
or otherwise transferring Consumer Products to parties that were, as of the Effective Date of this Agreement, end users and customers of Kimberly-Clark’s Global Consumer Business, specifically including the sale of Kimberly-Clark Consumer
Products to medical care facilities. 
 1.04 Consumer Products – Devices, products, articles or merchandise of common or
frequent use, ordinarily bought by individuals or households for private consumption from a retail outlet or otherwise obtained or provided direct to the consumer. Consumer Products expressly includes Kimberly-Clark Consumer Products. Consumer
Products do not include products, articles or merchandise sold by Kimberly-Clark’s Global Health Care Business as of the Effective Date of this Agreement. 

1.05 Effective Date – The date first written herein above. 

1.06 Halyard Competitor - A third party that manufactures, sells or distributes products of a type sold by Halyard. 

1.07 Health Care Market – End users whose primary business is the delivery of medical, veterinary or patient care or treatment,
medical diagnostic services, or medical care provided in connection with disaster relief, including, but not limited to: (1) professional medical and healthcare service companies, businesses, institutions and enterprises, (2) medical
diagnostics facilities and laboratories having patient interaction, (3) government and private organizations providing medical care in connection with disaster relief and (4) firms selling products or services into such end users; 

Such as: 
  

	 	•	 	Hospitals, including their pharmacies; 

  

	 	•	 	Integrated medical service provider networks and their member facilities; 

  

	 	•	 	Surgery centers, including their pharmacies; 

  

	 	•	 	Blood banks; 

  

	 	•	 	Bone and tissue centers; 

  
 Page 2 

	 	•	 	Physician and medical clinic offices including their pharmacies; 

  

	 	•	 	Psychiatric health facilities, including their pharmacies; 

  

	 	•	 	Clinics in retail outlets that perform or provide medical services or care; 

  

	 	•	 	Long-term medical care facilities, including their pharmacies; 

  

	 	•	 	Medical care components of the Red Cross or other disaster relief organizations; 

  

	 	•	 	Veterinary and other facilities that primarily provide medical care to animals; and 

  

	 	•	 	Dental care facilities.

 Notwithstanding anything to the contrary in this Agreement, Halyard and its Affiliates
may continue selling or otherwise transferring Medical Products to parties that were, as of the Effective Date of this Agreement, end users and customers of Kimberly-Clark’s Global Health Care Business. 

1.08 Kimberly-Clark Competitor - A third party that manufactures, sells or distributes products of a type sold by Kimberly-Clark. 

1.09 Kimberly-Clark Consumer Products - Consumer Products whose primary purpose is to help maintain or improve the hygiene, healthy
aging process and/or household care and maintenance of the end user. Such products include those intended to be used in connection with enuresis, incontinence, menstruation, personal hygiene, diaper rash, healthy skincare, household cleaning and
similar such fields, and may include medical devices, over-the-counter drugs or devices, prescription drugs or devices, or other regulated products or materials. Kimberly-Clark Consumer Products expressly include those products sold or otherwise
transferred to customers or end users by Kimberly-Clark’s Global Consumer Business as of the Effective Date of this Agreement. 
 1.10
Know How – Refers generally to engineering drawings, technical data, invention disclosures, reports, technical knowledge, methods, formulas, patterns, compilations, programs, devices, techniques, tests, drawings, processes, experience,
base and analytical science relating to the manufacture, testing, converting, packaging, handling, distributing and supplying of products and is inclusive of any and all trade secrets. 

1.11 Medical Products - Devices, products, articles, methods, systems or merchandise that are primarily utilized by (i) healthcare
professionals for the diagnosis, treatment or prevention of disease or injuries or (ii) caregivers under the direction and supervision of medical professionals in the treatment or prevention of disease or injuries. Medical Products expressly
include those devices, products, articles or merchandise sold or otherwise transferred to end users or customers in the Health Care Market by Kimberly-Clark’s Global Health Care Business as of the Effective Date of this Agreement. Medical
Products do not include devices, products, articles or merchandise sold by Kimberly-Clark’s Global Consumer Business as of the Effective Date of this Agreement. 

  
 Page 3 

 1.12 Patents – Refers generally to United States and foreign patents and patent
applications including any continuations, continuations-in-part, divisions, renewals, reissues and reexaminations thereof. The Appendices include lists of patents and patent applications that will be licensed from one party to the other. 

1.13 Professional Products – Devices, products, articles or merchandise whose primary purpose is to: 

 

	 	•	 	Help maintain facilities or manufacturing equipment; 

  

	 	•	 	Increase or improve employee and other individuals’: 

  

	 	•	 	efficiency, 

  

	 	•	 	safety or protection; or 

  

	 	•	 	cleanliness; 

  

	 	•	 	Enhance the safety or cleanliness or efficiency of facilities or equipment or processes. 

 Professional
Products expressly include those devices, products, articles or merchandise sold or otherwise transferred to customers or end users by Kimberly-Clark’s Global Professional Business and Global Partnership Products Business as of the Effective
Date of this Agreement. 
 1.14 Professional Market – End users whose primary business is performed in an industrial,
commercial, or institutional setting, including but not limited to: 
 (1) Manufacturing facilities or factories; 

(2) Repair and service facilities (e.g. equipment, machines, vehicles, etc.); 

(3) Lodging, entertainment and hospitality facilities; 

(4) Professional offices other than components directed to the provision of medical care and treatment to patients; 

(5) Food preparation and processing facilities; 

(6) Facilities directed to natural resource extraction and processing (e.g. mining, drilling, refining, etc.); 

(7) Schools and academic institutions (including research laboratories in hospitals associated with academic institutions); 

(8) Technology development, research, or scientific facilities or labs; 

(9) Non-medical care components of relief agencies; 

(10) Non-medical care components of long term medical care facilities; 

(11) Pharmacies other than components directed to the provision of medical care and treatment to patients; 

(12) Components of hospitals, clinics or other medical care facilities other than those that relate to the diagnosis, treatment or prevention
of disease, injury or a medical condition or other activities that are typically administered by or under the direction of a medical professional (e.g. laboratory work, facility maintenance, janitorial services, etc.); 

  
 Page 4 

 (13) Non-veterinary care components of animal shelters or animal care facilities; and 

(14) Firms selling products or services into such end users. 

The Professional Market specifically does not include the patient interaction components of veterinary facilities, hospitals, pharmacies, medical care
facilities and/or components of such facilities used for the delivery of medical care. Notwithstanding anything to the contrary herein, KCWW and its Affiliates may continue selling or otherwise transferring Professional Products to the end users and
customers of Kimberly-Clark’s Global Professional Business and Global Partnership Products Business as of the Effective Date of this Agreement. 

ARTICLE 2 
 PATENT AND KNOW HOW
LICENSE GRANTS 
 2.01 Specific license grants from Licensor to Licensee are set forth in Appendix A - G. The licenses in this Agreement
include the right to sublicense to Affiliates. However, unless otherwise specifically provided in the license grants of Appendix A - G, the licenses in this Agreement do not include the right to sub-license to any other third party. The license
grants are limited to the Patents and Know How specifically enumerated in each Appendix and do not include any rights to Know How or Patents that are not listed or improvements to Patents or Know How made by either party after the Effective Date of
this Agreement. Notwithstanding the foregoing, in the event that Licensor chooses in their sole discretion to pursue patent protection for an invention that is the subject to a license by being included as Know How, Licensee will have rights to any
Patent that matures from such an invention commensurate with the rights Licensor has to the Patents in the subject license. 
 2.02 Nothing
in this Agreement shall obligate Licensor to maintain any or all licensed Patents. Notwithstanding the foregoing, in the event that Licensor decides to allow a Patent to lapse or become abandoned, Licensor shall take reasonable efforts to provide
notice of such decision to Licensee at least thirty (30) days prior to the date of lapse or abandonment of the Patent. Licensee then has up to ten (10) business days following such notification to inform Licensor as to whether or not it
will take action to prevent the lapse or abandonment of the Patent and have ownership of the Patent transferred to Licensee. A lack of timely response by the Licensee shall be deemed to indicate that the Licensee has no interest in the Patent that
is slated to lapse or be abandoned. Any action taken by Licensee to prevent the lapse or abandonment of a Patent and have ownership transferred to Licensee shall be at Licensee’s expense. 

ARTICLE 3 
 CONFIDENTIALITY

 3.01 Neither party shall, without the prior written consent of the other party, directly or indirectly disclose to any third party,
or permit anyone on its behalf to disclose to any third-party, any Confidential Information obtained pursuant to and/or in connection with this Agreement, and both parties shall use such measures to protect all such Confidential Information that it
would use in the protection of its own confidential information, and in any event no less than reasonable care. The obligations in this Section 3.01 shall continue during the term of this Agreement and for ten (10) years

  
 Page 5 

 thereafter (or such shorter period as required by applicable law); provided that with respect to any Confidential
Information that is protectable as a trade secret, such obligations shall continue in perpetuity (or until the earlier occurrence of one of the exceptions in Section 3.02). Notwithstanding the foregoing, this Article 3 will not preclude the
owner of Confidential Information from seeking patent protection concerning such Confidential Information. 
 3.02 The obligations under
Section 3.01 shall not apply to Confidential Information that, as evidenced by written documentation: (a) was received by such party on a non-confidential basis from a third party having the right to impart such information; (b) was
generally known or generally available to the public prior to the Effective Date of this Agreement; or (c) becomes generally known or generally available to the public after the Effective Date of this Agreement through no act or failure to act
on the part of such party. Confidential Information shall not be deemed to be part of the public domain merely because such information may be contained within substantially less specific broad disclosures or combinations of disclosures. 

ARTICLE 4 
 MARKING 

For the life of the U.S. Patents, both parties shall mark in accordance with applicable laws all products sold, offered for sale, or otherwise
disposed of by it within the United States, its territories, or possessions, with the word “Patent” or “Patents” and the number or numbers of the applicable U.S. Patents being practiced on a visible surface thereof or on the
package, tags, labels, manuals, or other associated materials. It is acceptable to mark by referring to lists of patents included on some other publicly available location such as an internet site. 

ARTICLE 5 
 INFRINGEMENTS OF
PATENTS 
 5.01 Licensee shall notify Licensor promptly and fully of any infringement of any Patent which comes to its
notice. Licensor shall take such steps as Licensor in its sole discretion shall deem advisable to abate infringements of Patents, including, if Licensor shall so decide, the bringing of a lawsuit. When requested by Licensor, Licensee may
at its sole discretion cooperate, at Licensor’s expense, in the conduct of such lawsuit. After deductions for expenses incurred, Licensor and Licensee shall participate on a fair and equitable basis in any money damages recovered. 

5.02 Should Licensor elect not to bring a lawsuit with respect to infringement of any Patent, Licensee may, with Licensor’s written
consent, which shall not be unreasonably withheld, bring a lawsuit, either in Licensee’s own name or jointly with Licensor. Licensee shall be solely responsible for any and all costs associated with such lawsuits and including costs
related to the defense of any counterclaim thereto and/or any civil or administrative challenges as to the validity of the Patent. When requested by Licensee, Licensor may at its sole discretion cooperate, at Licensee’s expense, in the
conduct of such lawsuit. After deductions for expenses incurred, Licensor and Licensee shall participate on a fair and equitable basis in any money damages recovered. 

  
 Page 6 

 ARTICLE 6 

ASSIGNMENT 
 This
Agreement and all rights and obligations hereunder may not be assigned by either party without the express prior written consent of the other party, except that this Agreement shall be binding upon and inure to the benefit of a third party that
acquires either party’s entire or substantially entire business, subject to Section 7.04 below. Any assignment or attempt at the same in the absence of prior written consent required by this paragraph shall be void and without effect.
Notwithstanding the foregoing, either party may, with written notice to the other party, assign this Agreement to a wholly owned Affiliate. 

ARTICLE 7 
 TERM AND
TERMINATION 
 7.01 Term. This Agreement shall commence on the Effective Date and shall terminate upon expiration of the last to
expire of the Patents except that any license to Know How shall last indefinitely or until such Know How becomes generally known or generally available to the public. 

7.02 Termination for Breach by Licensee. In the event Licensee breaches any of its representations or material obligations under this
Agreement, Licensor may terminate this Agreement and the license granted in this Agreement by giving notice in writing to Licensee of the breach. In the event Licensee does not correct or eliminate the breach within thirty (30) days from the
date of receipt of such notice, this Agreement, including the license to use the Licensed Patents and Know How, shall terminate ten (10) days following the thirty (30) day cure period. 

7.03 Termination for Breach by Licensor. In the event Licensor breaches any of its representations or material obligations under this
Agreement, Licensee may terminate this Agreement and the license granted in this Agreement by giving notice in writing to Licensor of the breach. In the event Licensor does not correct or eliminate the breach within thirty (30) days from the
date of receipt of such notice, this Agreement, including the license to use the Licensed Patents and Know How, shall terminate ten (10) days following the thirty (30) day cure period. 

7.04 Termination for Change of Control. Licensor will have the right to terminate this Agreement and the licenses granted in this
Agreement by giving written notice to Licensee in the event of a Change of Control of Licensee. A “Change of Control” means a transaction in which there is a change in the person or persons holding a controlling interest in the equity of
Licensee (or in the equity of any parent entity of Licensee) and such change results in the controlling interest in the Licensee or such parent entity being held by a Kimberly-Clark Competitor. 

7.05 Failure to Spin Off the Health Care Business. If for any reason Kimberly-Clark should elect not to spin off the Health Care
Business, then this Agreement shall be void ab initio. 

  
 Page 7 

 ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 

8.01 Representations and Warranties. Each of the parties represents and warrants that it has authority to enter into this Agreement and
to perform its obligations under this Agreement and that it has been duly authorized to execute and to deliver this Agreement. 
 8.02 No
Other Representations or Warranties. Other than specifically provided for elsewhere in this Article, nothing in this Agreement shall be construed as: 
  

	 	(a)	a warranty or representation by either party as to the validity, enforceability, or scope of any of the Patents or Know How; 

  

	 	(b)	a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents or third parties; 

 

	 	(c)	an obligation to furnish any manufacturing or technical information, or any information concerning pending patent applications; 

  

	 	(d)	granting by implication, estoppel, or otherwise any licenses or rights under patents other than the Patents; or 

  

	 	(e)	a requirement that either party maintain, defend or enforce any licensed Patent. 

 ARTICLE 9

 LIMITATIONS AND INDEMNIFICATION 

9.01 With respect to the use of any and all Patents and Know-How, Licensee shall be and remain solely responsible and liable for identifying
and making determinations regarding (i) the suitability of any good or service for a particular purpose, (ii) any health and safety issues associated with the handling, processing and/or use of any good or service, (iii) accuracy of
all specifications for any good or service, and (iv) compliance of any good or service with associated regulatory or other governmental requirements. 

9.02 Licensee shall indemnify and hold Licensor and Licensor’s Affiliates harmless from or against any losses, claims, damages and
expenses arising out of or resulting from Licensee’s use of the Patents and Know-How after the Effective Date. 

  
 Page 8 

 ARTICLE 10 

NOTICES 
 All notices and
communications in connection with this Agreement shall be in writing and shall be deemed sufficient and delivery thereof shall be complete on the day of receipt if sent by KCWW by overnight commercial carrier to: 

Avent Inc. 
 5405 Windward
Parkway, Suite 100, South 
 Alpharetta, Georgia 30004 

ATTENTION: General Counsel 
 or if sent by Avent
by overnight commercial carrier to: 
 Kimberly-Clark Worldwide, Inc. 

2100 Winchester Road 
 Neenah, WI
54956 
 ATTENTION: General Counsel 
 or any
other address and to the attention of any other officer or person as each of the parties hereto may specify by written notice to the other. 

ARTICLE 11 
 SEVERABILITY OF
PROVISIONS 
 If any provision of this Agreement shall be held to be invalid, illegal or unenforceable in any jurisdiction, the validity
and enforceability of the remaining provisions shall not be affected thereby in such jurisdiction nor shall the validity or enforceability of such provisions, or this Agreement as a whole, be affected thereby in any other jurisdiction. 

ARTICLE 12 
 HEADINGS 

Article and paragraph headings used in this Agreement are for the purpose of reference only and shall not be considered in construing this
Agreement. 
 ARTICLE 13 

COMPLIANCE WITH LAW 

Nothing in this Agreement shall require KCWW or Avent to violate any applicable law. 

ARTICLE 14 
 WAIVER OF BREACH

 No waiver of breach of any of the provisions of this Agreement shall be construed to be a waiver of any succeeding breach of the same
or any other provision. 

  
 Page 9 

 ARTICLE 15 

ENTIRE AGREEMENT 
 This
Agreement constitutes the entire agreement between the parties relating to the subject matter hereof, and supersedes any and all prior or contemporaneous agreements, whether oral or written, relating to the subject matter hereof. No amendment or
change in this Agreement shall be valid unless made in writing and signed by both parties. 
 ARTICLE 16 

APPLICABLE LAW 
 This
Agreement shall be construed in accordance with the substantive laws of the State of Delaware of the United States of America, without regard to its conflict of laws provisions. Both parties to this Agreement submit to the personal jurisdiction of
any court of competent subject matter jurisdiction located in the State of Delaware of the United States of America. 
 ARTICLE 17 

FORCE MAJEURE 
 Neither
KCWW nor Avent shall be liable to the other for any failure to comply with any terms of the Agreement to the extent any such failure is caused directly or indirectly by fire, strike, union disturbance, or other industrial dispute, war (whether or
not declared), acts or the threat of terrorism, riots, insurrection, government restrictions or other government acts, or other causes beyond the reasonable control of either KCWW or Avent. Upon the occurrence of any event of the type referred to in
this Article, the party affected thereby shall give prompt notice thereof to the other party, together with a description of such event and the duration for which such party expects its ability to comply with the provisions of this Agreement shall
be affected thereby. The party so affected shall thereafter devote reasonable commercial efforts to remedy to the extent possible the condition giving rise to such event and to resume performance of its obligations hereunder as promptly as possible.

 ARTICLE 18 
 FURTHER
INSTRUMENTS AND ACTS 
 The parties agree to execute, acknowledge and deliver all such further instruments, and to do all such other
acts, as may be necessary and appropriate in order to effectuate this Agreement. 

  
 Page 10 

 ARTICLE 19 

RELATIONSHIP BETWEEN THE PARTIES 

This Agreement does not, and shall not be deemed to, designate either party as the agent or legal representative of the other party for any
purpose whatsoever. Neither party is granted, nor shall such party be deemed to be granted, any right or authority under this Agreement to assume or create any obligation or responsibility, expressed or implied, on behalf of or in the name of the
other party or to bind the other party in any manner or thing whatsoever. No joint venture, association or partnership between KCWW and Avent is intended or shall be deemed to be created as a result of this Agreement. 

ARTICLE 20 
 COUNTERPARTS

 This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same document. 
 IN WITNESS WHEREOF, the parties have caused their authorized representatives
to execute this Agreement. 
  

			
		 	KIMBERLY-CLARK WORLDWIDE, INC.
		
	By:	 	  

	Title:	 	
		
		 	AVENT, INC.
		
	By:	 	  

	Title:	 	

  
 Page 11 

 APPENDIX A – ANTI-VIRAL TECHNOLOGY 

Patents and Know How: “Anti-Viral Technology” refers to delivery systems for anti-viral agents and is limited to the
following Know How and Patents: 
 License: KCWW hereby grants to Avent a royalty-free, worldwide, irrevocable, exclusive license to
make, have made, use, import, offer for sale, and sell Medical Products in the Health Care Market under the Patents and Know How set forth above in this Appendix A. 

Term: The term of this Anti-Viral Technology license shall end upon expiration of the last to expire of the licensed Anti-Viral
Technology Patents except that any license to Anti-Viral Technology Know How shall last indefinitely or until such Know How becomes generally known or generally available to the public. 

  
 Page 12 

 APPENDIX B – APPLICATORS & DRESSINGS TECHNOLOGY 

Patents and Know How: “Applicators & Dressings Technology” refers to liquid applicators, delivery of skin wellness
agents and wound dressings and is limited to the following Know How and Patents: 
 License: KCWW hereby grants to Avent a
royalty-free, worldwide, irrevocable, exclusive license to make, have made, use, import, offer for sale, and sell Medical Products in the Health Care Market under the Patents and Know How set forth above in this Appendix B. 

Term: The term of this Applicators & Dressings Technology license shall end upon expiration of the last to expire of the
licensed Applicators & Dressings Technology Patents except that any license to Applicators & Dressings Technology Know How shall last indefinitely or until such Know How becomes generally known or generally available to the public.

  
 Page 13 

 APPENDIX C – FLEXIBLE BINDERS TECHNOLOGY 

Patents and Know How: “Flexible Binders Technology” refers to flexible superabsorbent binders and coatings and is limited to
the following Know How and Patents: 
 License: KCWW hereby grants to Avent a royalty-free, worldwide, irrevocable, exclusive license
to make, have made, use, import, offer for sale, and sell Medical Products in the Health Care Market under the Patents and Know How set forth above in this Appendix C. 

Term: The term of this Flexible Binders Technology license shall end upon expiration of the last to expire of the licensed Flexible
Binders Technology Patents except that any license to Flexible Binders Technology Know How shall last indefinitely or until such Flexible Binders Technology Know How becomes generally known or generally available to the public. 

  
 Page 14 

 APPENDIX D – CR&E TECHNOLOGIES 

Patents and Know How: “CR&E Technologies” refers to technology developed by Kimberly-Clark’s Corporate Research and
Engineering team having relevance to Medical Products and is limited to the following Know How: 
 License: KCWW hereby grants to
Avent a royalty-free, worldwide, irrevocable, non-exclusive license to make, have made, use, import, offer for sale, and sell Medical Products in the Health Care Market under the Know How set forth above in this Appendix D. 

Term: The term of this CR&E Technologies shall last indefinitely or until such CR&E Technologies Know How becomes generally
known or generally available to the public. 

  
 Page 15 

 APPENDIX E – WOUND CARE TECHNOLOGY 

Patents and Know How: “Wound Care Technology” refers to wound care formulations including peptide sequences to reduce
chrondrosarcoma and various formulations to promote skin wellness and is limited to the following Know How and Patents: 
 License:
KCWW hereby grants to Avent a royalty-free, worldwide, irrevocable, non-exclusive license to make, have made, use, import, offer for sale, and sell Medical Products in the Health Care Market under the Patents and Know How set forth above in this
Appendix E. 
 Term: The term of this “Wound Care Technology” license shall end upon expiration of the last to expire of
the licensed Wound Care Technology Patents except that any license to Wound Care Technology Know How shall last indefinitely or until such Wound Care Technology Know How becomes generally known or generally available to the public. 

  
 Page 16 

 APPENDIX F – OTHER K-C TECHNOLOGY 

Patents and Know How: “Other K-C Technology” refers to sterilization packaging, indicators, elder care methods and pathogen
selective wipes and is limited to the following Know How and patents: 
 License: KCWW hereby grants to Avent a royalty-free,
worldwide, irrevocable, exclusive license to make, have made, use, import, offer for sale, and sell Medical Products in the Health Care Market under the Patents and Know How set forth above in this Appendix F. 

Term: The term of this Other K-C Technology license shall end upon expiration of the last to expire of the licensed Other K-C
Technology Patents except that any license to Other KCWW Technology Know How shall last indefinitely or until such Other K-C Technology Know How becomes generally known or generally available to the public. 

  
 Page 17 

 APPENDIX G – GNW TECHNOLOGY 

Patents: “GNW Patents” refers to Patents relating to the manufacture and use of nonwoven fabrics and film/nonwoven laminates
used to produce infection control products including sterile wrap, surgical drapes, face masks, medical equipment covers, and protective apparel, and is limited to the following Patents: 

BSFL Know How: Breathable Spunbond/Film Laminate (BSFL) Know How – All technology associated with the design, operation and
maintenance of the methods of making, treating, converting, testing, packaging, and handling breathable spunbond/film laminates as such equipment and methods exist on the Effective Date of this Agreement. 

License: KCWW hereby grants to Avent a royalty-free, worldwide, irrevocable, exclusive license to make, have made, use, import, offer
for sale, and sell Medical Products in the Health Care Market under the Patents set forth above in this Appendix G. 
 Option: KCWW
further grants Avent an option to receive from KCWW a royalty-free, irrevocable, non-exclusive license to make and use BSFL Know How at the Lexington Mill; such option exercisable for a period of five (5) years from the Effective date upon
Avent’s acquisition of film manufacturing equipment at the Lexington Mill. 
 Term: The term of the GNW Patents license shall
end upon expiration of the last to expire of the licensed GNW Patents. Should Avent exercise its option to the BSFL Know How license, such license shall last indefinitely or until such BSFL Know How becomes generally known or generally available to
the public. 

  
 Page 18EX-10.9

 Exhibit 10.9 

TRADEMARK LICENSE AGREEMENT 

This Trademark License Agreement (this “Agreement”), effective as of
            , 2014 (the “Effective Date”), is made and entered by and between Kimberly-Clark Worldwide, Inc., a Delaware corporation (“Licensor”); and
Avent, Inc., a Delaware corporation (“Licensee”). 
 RECITALS 

WHEREAS, Licensor is a wholly-owned subsidiary of Kimberly-Clark Corporation
(“Kimberly-Clark”) and, as of the Effective Date, Licensee will be a wholly-owned subsidiary of Halyard Health, Inc. (“Halyard”); and 

WHEREAS, Licensor has adopted, used and is the owner of the certain trademarks for certain goods, as
identified below; and 
 WHEREAS, Licensor wishes to grant to Licensee, and Licensee desires to obtain
from Licensor, a license to use said trademarks on or in connection with the manufacture, distribution, marketing, advertising, promotion and sale of medical and healthcare products and related services, on the terms and conditions described in this
Agreement; 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and obligations
contained herein, the parties agree as follows: 
 1. Definitions. As used in this Agreement, the following terms shall have the
following meanings. Capitalized terms used but not otherwise defined elsewhere in this Agreement shall have the respective meanings given to such terms in the Distribution Agreement by and between
Kimberly-Clark and Halyard dated as of             , 2014 (the “Distribution Agreement”). 

1.1 “Affiliate” shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled
by or is under common control with such Person. For the purpose of this definition, the term “control” means the power to direct the management of an entity, directly or indirectly, whether through the ownership of voting securities, by
contract or otherwise; and the term “controlled” has the meaning correlative to the foregoing. After consummation of the Distribution Agreement, Halyard and Kimberly-Clark shall not be deemed to be under common control for purposes hereof
due solely to the fact that Halyard and Kimberly-Clark have common stockholders. Notwithstanding the foregoing definition, Hogla-Kimberly, Kimberly-Clark de Mexico, Kimberly-Clark Lever Private Limited and
Olayan Kimberly-Clark are Affiliates of Kimberly-Clark. 
 1.2 “Change of Control” shall mean a transaction in which there
is a change in the person or persons holding a controlling interest in the equity of Licensee (or in the equity of any parent entity of Licensee) and such change results in the controlling interest in the Licensee or such parent entity being held by
a Kimberly-Clark Competitor. 

 1.3 “Kimberly-Clark Competitor” shall mean a third party that manufactures,
sells or distributes products of a type sold by Kimberly-Clark. 
 1.4 “Licensed Marks” shall mean (a) the marks shown
in Appendix A attached hereto, including the marks that are the subject of the registrations and applications identified in Appendix A; (b) marks that include or incorporate such marks; and (c) any variants or formatives thereof, each as
used on, for and in connection with products intended to be used by providers of medical and healthcare services or their patients. 

1.5 “Medical Products” shall mean devices, products, articles, methods, systems or merchandise on or in connection with which
the Licensed Marks are used and that are primarily utilized by (a) healthcare professionals for the diagnosis, treatment or prevention of disease or injuries or (b) caregivers under the direction and supervision of medical professionals in
the treatment or prevention of disease or injuries. Medical Products expressly include those devices, products, articles or merchandise sold or otherwise transferred to end users or customers in the Health Care Market by Kimberly-Clark’s Global
Healthcare Business as of the Effective Date of this Agreement. Medical Products do not include devices, products, articles or merchandise sold by Kimberly-Clark’s Global Consumer Business as of the
Effective Date of this Agreement. 
 1.6 “Health Care Market” shall mean end users whose primary business is the delivery
of medical, veterinary or patient care or treatment, medical diagnostic services, or medical care provided in connection with disaster relief, including, but not limited to: (a) professional medical and healthcare service companies, businesses,
institutions and enterprises, (b) medical diagnostics facilities and laboratories having patient interaction, (c) government and private organizations providing medical care in connection with disaster relief, and (d) firms selling
products or services into such end users; examples of such end users are: 
  

	 	•	 	Hospitals, including their pharmacies; 

  

	 	•	 	Integrated medical service provider networks and their member facilities; 

  

	 	•	 	Surgery centers, including their pharmacies; 

  

	 	•	 	Blood banks; 

  

	 	•	 	Bone and tissue centers; 

  

	 	•	 	Physician and medical clinic offices, including their pharmacies; 

  

	 	•	 	Psychiatric health facilities, including their pharmacies; 

  

	 	•	 	Clinics in retail outlets that perform or provide medical services or care; 

  

	 	•	 	Long-term medical care facilities, including their pharmacies; 

  

	 	•	 	Medical care components of the Red Cross or other disaster relief organizations; 

  
 - 2 - 

	 	•	 	Veterinary and other facilities that primarily provide medical care to animals; and 

  

	 	•	 	Dental care facilities.

 Notwithstanding anything to the contrary in this Agreement, Halyard and its Affiliates
may continue selling or otherwise transferring Medical Products to parties that were, as of the Effective Date of this Agreement, end users and customers of Kimberly-Clark’s Global Healthcare Business. 

2. Grant and Scope of License 

2.1 Grant of License. Subject to the terms and conditions of this Agreement, Licensor grants to Licensee, and to all Affiliates of
Licensee , and Licensee accepts an exclusive, non-transferable (unless transferred in compliance with Section 8.1) license, for the term stated in this Agreement, subject to the payment of royalties as provided in Exhibit A to this Agreement,
to use throughout world the Licensed Marks: 
 (a) on or in connection with Medical Products that are marketed solely
to the Health Care Market; 
 (b) in connection with manufacturing the Medical Products and distributing the Medical
Products solely to the Health Care Market; and 
 (c) in connection with marketing, advertising, promotion, and/or
sale of the Medical Products solely to the Health Care Market, including such use by Licensee’s authorized sales representatives. 
 All of the
foregoing uses identified in paragraphs 2.1(a) through 2.1(c) shall hereinafter be referred to collectively as the “Licensed Uses.” 

2.2 Limited Purpose. Licensee shall not use the Licensed Marks in connection with any activities other than the Licensed Uses without
prior written approval of Licensor. All rights not expressly granted herein to Licensee are specifically reserved to and vested in Licensor, including the right to use or authorize others to use the Licensed Marks in connection with Medical
Products, provided such products are marketed and sold to parties other than those in the Health Care Market. Notwithstanding the foregoing and for the sake of clarity, Licensor shall not directly market or sell products bearing the Licensed Marks
to the Health Care Market. 
 2.3 Compliance by Affiliates. Licensee agrees that Licensee shall be responsible for ensuring and
guaranteeing compliance by all Affiliates of Licensee with all of the terms, conditions and provisions of this Agreement. Licensee represents and warrants to Licensor that Licensee has the power and authority to cause all such Affiliates to comply
with all such terms, conditions and provisions, and acknowledges that such compliance shall be a condition to the lawful exercise by any of Licensee’s Affiliates of any of the rights granted in this Agreement to Licensee. 

  
 - 3 - 

 3. Compliance Issues 

3.1 Form of Use. Licensee shall use the Licensed Marks only in forms and presentations that have been approved in advance, in writing,
by Licensor. All forms and presentations in use by Kimberly-Clark’s Global Healthcare Business as of the Effective Date are hereby deemed approved by Licensor. Once any such form or presentation has been approved by Licensor, Licensee’s
use of the Licensed Marks in such form or presentation shall not be restricted; provided, however, that Licensor may, for Good Reason (as defined herein) object to a previously-approved form or presentation by giving Licensee written notice of
Licensor’s objection and the reasons for the objection (a “Notice of Objection”). Licensee shall timely comply with and correct all objections set forth in the Notice of Objection. For purposes of this Agreement, “Good
Reason” shall mean a reason based on trademark law principles (including but not limited to principles relating to maintenance of trademark validity and/or integrity, proper trademark usage, and brand identity) that, in Licensor’s
opinion, justifies Licensor’s objection, so long as such Notice of Objection proposes an alternative form or presentation that is as similar to the previously-approved form or presentation as is consistent, in Licensor’s opinion, with such
trademark law principles. 
 3.2 Marking. Licensee shall include, where appropriate and as requested by Licensor, agreed-to trademark
markings or legends for the Licensed Marks. Licensee shall comply with all applicable laws and regulations pertaining to the proper use and designation of trademarks. 

3.3 Use of Other Marks. Licensee shall not use during the term of this Agreement or thereafter without the written consent of Licensor
any name, mark, designation or design that is likely to cause confusion with any of the Licensed Marks, including any mark (other than the Licensed Marks) that begins with or includes “KIM.” 

4. Quality Control and Use of Licensed Marks 

4.1 Quality Control. Licensor shall at all times retain the right, in its sole discretion, to control the nature and quality of all
Medical Products in accordance with applicable trademark law. Licensee shall comply with all requests or instructions of Licensor relating to the nature or quality of the Medical Products, and shall comply with all quality control guidelines of
Licensor, as adopted from time to time by Licensor in writing and provided to Licensee. Licensor and Licensee intend the quality control provisions of this Section 4 to require Licensee to maintain the nature and quality of the Medical Products
as required by Licensor, so as to maintain the validity and integrity of the Licensed Marks, as required by applicable law. 
 4.2
Quality Standards. In furtherance of its quality control rights and obligations set forth in Section 4.1 above, Licensor has furnished to Licensee quality standards applicable to goods bearing the Licensed Marks as of the Effective Date.
Licensee shall ensure that all Medical Products conform to the quality standards historically associated with the products of Licensor on which the Licensed Marks have been used prior to the Effective Date, and with such quality standards as
Licensor may reasonably adopt after the Effective Date and communicate in writing to Licensee. Licensee represents that, as a principal part of its business, 

  
 - 4 - 

 
it has acquired all the necessary and appropriate knowledge, skill, experience and expertise to enable it to manufacture, inspect, test, approve, market, advertise, promote, distribute and sell
Medical Products in compliance with Licensor’s existing quality standards, including with respect to their performance and safety, in compliance with all applicable laws and regulations, and acknowledges and agrees that, as a result thereof,
Licensor may reasonably rely on Licensee to regularly ensure that all Medical Products comply with such quality standards, laws and regulations. Nothing contained herein, however, shall preclude or limit Licensor’s right or ability to inspect
any Medical Products or to determine, in Licensor’s reasonable discretion, whether such Medical Products comply with the quality standards communicated by Licensor to Licensee in accordance with this Section 4.2. Licensee shall cooperate
fully with Licensor, as requested by Licensor, in connection with any such inspection or determination by Licensor. Licensor and Licensee agree that any subsequent adoption of different quality standards with which Licensee must comply may be made
to maintain compliance of all Medical Products with applicable laws and regulations, and Licensor agrees that any different quality control standards adopted during the term of this Agreement shall be reasonable and consistent with the nature and
qualities of the products of Licensor on which the Licensed Marks have been used in the past. 
 4.3 Compliance with Law. Licensee
shall comply with all applicable laws and regulations and obtain all appropriate government approvals pertaining to its use of the Licensed Marks, including the Licensed Uses and Licensee’s manufacture, sale, distribution, marketing,
advertising and promotion of products on or in connection with which the Licensed Marks are used. 
 4.4 No Disparagement of Licensor or
Licensed Marks. Licensee shall not use the Licensed Marks in connection with any activity that disparages Licensor, its products or services, or the Licensed Marks. 

4.5 Licensor’s Maintenance of Licensed Marks. Licensor shall take no actions that derogate or devalue the Licensed Marks, and
agrees to make reasonable efforts to maintain the goodwill of the Licensed Marks, as well as any registrations for, and applications for registration of, the Licensed Marks. Licensee agrees to cooperate with Licensor or its representatives by timely
obtaining and/or submitting to Licensor or its representatives, as requested by Licensor, documents, information, specimens, verified or sworn statements, assignments or other documents reasonably believed by Licensor to be necessary in order to
maintain such registrations or prosecute applications for the Licensed Marks. 
 5. Ownership 

5.1 Ownership of Licensed Marks. Licensee acknowledges that Licensor will remain the sole and exclusive owner of all right, title and
interest in and to the Licensed Marks. Licensee agrees that any goodwill in the Licensed Marks resulting from Licensee’s use of the Licensed Marks under this Agreement will inure solely to the benefit of Licensor and will not create any right,
title or interest of Licensee (including any ownership right by Licensee) in or to the Licensed Marks. 

  
 - 5 - 

 5.2 No Contest. Licensee shall not contest, oppose or challenge Licensor’s ownership
of the Licensed Marks or the validity thereof. Licensee will do nothing to impair Licensor’s ownership or rights in the Licensed Marks. In particular, Licensee shall not register or attempt to register any of the Licensed Marks, alone or with
other words or designs, in any country or jurisdiction, and will not oppose or contest Licensor’s application(s) to register, registration(s) or permitted use(s) of the Licensed Marks in any jurisdiction. 

5.3 Adverse Use and Enforcement 

(a) Notice. Each party shall promptly notify the other party in writing of any legal proceeding or action instituted against such party
arising out of the use of or involving the Licensed Marks. Each party shall also promptly notify the other party in writing should such party learn of use by an unauthorized third party of any mark that may be confusingly similar to, infringe or
otherwise violate Licensor’s rights in one or more of the Licensed Marks or Licensee’s exclusive rights under this Agreement. 

(b) Enforcement. Except as provided for below, Licensor shall have the sole right and discretion to enforce its rights in any of the
Licensed Marks, including but not limited to the right to bring infringement, unfair competition, dilution or false advertising proceedings involving any of the Licensed Marks. Licensee shall cooperate fully to assist Licensor and its attorneys or
other authorized agents, at Licensor’s expense, with any legal, equitable, administrative, regulatory or other proceeding or action taken by Licensor against a third party to protect the Licensed Marks. Notwithstanding the foregoing, if, within
twenty (20) days of Licensor’s receipt of a notice from Licensee in accordance with paragraph (a) above, Licensor does not agree in writing to bring or take action to terminate such activities of the unauthorized third party, or if
Licensor subsequently decides not to proceed with any such action, and if Licensee has a good faith belief that such activities have or will injure its rights under this Agreement, then Licensee may take such action as is reasonably necessary to
halt such activities including filing suit, after providing written notice to Licensor at least seven (7) days in advance of taking such action. Whichever party takes action against such activities shall be responsible for the costs and fees of
such action including payment of both Licensor’s and Licensee’s attorneys’ fees, costs and expenses, and the other party shall, if requested, cooperate in such action as shall be reasonably necessary (including joining as a party
plaintiff to the extent necessary and requested by the other party), but again at the cost of the party taking action. Any monies recovered as a result of such action shall first be used to pay the legal expenses of the party that took such action
and the legal fees of the party cooperating in such action and any remaining amounts after reimbursement of such fees shall be retained by, paid to or recovered by the party that initiated the action. 

6. Indemnification 

6.1 By Licensor. Licensor shall defend, indemnify and hold harmless Licensee and its respective parents, subsidiaries, and otherwise
related entities, agents, servants, current and former officers, directors and employees, shareholders, attorneys, successors and assigns, against all claims, liabilities, damages, losses, costs, settlement amounts and expenses (including expenses
of litigation and/or attorneys’ fees) arising out of or in connection with any 

  
 - 6 - 

 
claims, legal proceedings or actions instituted or asserted against Licensee or Licensor for trademark infringement arising out of Licensee’s use of the Licensed Marks in accordance with
this Agreement (an “Indemnified Claim”); and Licensor shall defend or settle any such claims, legal proceedings or actions instituted against Licensee or Licensor at no expense to Licensee or Licensee’s Affiliates, employees,
officers, directors, or authorized sales representatives; PROVIDED THAT Licensee shall give to Licensor prompt written notice of any Indemnified Claim following Licensee’s receipt of written notification of such claim, legal proceeding or
action instituted by a third party against Licensee; and PROVIDED FURTHER THAT Licensee shall not enter into any negotiation or settlement regarding any Indemnified Claim and shall provide to Licensor the full authority to defend or settle the
claim. Licensee shall cooperate fully in the defense of such claim at Licensor’s expense. Licensee may participate in any such claim at its own expense with counsel of its choosing. 

6.2 By Licensee. Except with respect to Indemnified Claims as defined in the foregoing Section, Licensee shall defend, indemnify and
hold harmless Licensor and its respective parents, subsidiaries, and otherwise related entities, agents, servants, current and former officers, directors and employees, shareholders, attorneys, successors and assigns, against all claims,
liabilities, damages, losses, costs, settlement amounts and expenses (including expenses of litigation and/or attorneys’ fees) arising out of or in connection with any claims, legal proceedings or actions instituted or asserted against Licensee
or Licensor arising in whole or in part from any activities of Licensee relating to the Licensed Marks or the Medical Products, including but not limited to: (i) alleged defects or deficiencies in the Medical Products offered by Licensee;
(ii) Licensee’s agreements, policies, promises, or activities relating to the provision or advertising of the Medical Products; (iii) alleged violations of any applicable law or regulation relating to the Medical Products offered by
Licensee; (iv) alleged acts of piracy, plagiarism, infringement, fraud, larceny/theft, libel or invasion of privacy; and/or (v) any allegations by third parties asserting claims of fraud, negligence, or gross negligence relating to the
provision of the Medical Products. Licensor shall promptly notify Licensee in writing of any such claims asserted against Licensor. 
 7.
Term and Termination 
 7.1 Term. The term of this Agreement shall commence on the Effective Date and continue for a term of two
(2) years, unless terminated at an earlier time in accordance with the provisions of this Agreement. 
 7.2 Termination by Licensor

 (a) Breach. In the event Licensee breaches any of its material obligations under this Agreement, Licensor may terminate this
Agreement and the license granted in this Agreement by giving notice in writing to Licensee of the breach. In the event Licensee does not correct or eliminate the breach within thirty (30) days from the date of receipt of such notice, this
Agreement, including the license to use the Licensed Marks, shall terminate ten (10) days following the thirty (30) day cure period. In the event Licensor breaches any of its representations or material obligations under this Agreement, Licensee may
terminate this Agreement and the license granted in this Agreement by giving notice in writing to Licensor of 

  
 - 7 - 

 the breach. In the event Licensor does not correct or eliminate the breach within thirty (30) days from the
date of receipt of such notice, this Agreement, including the license to use the Licensed Marks, shall terminate ten (10) days following the thirty (30) day cure period. 

(b) Change of Control. Licensor will have the right to terminate this Agreement and the license granted in this Agreement by giving
written notice to Licensee in the event of a Change of Control of Licensee. 
 (c) Threat of Infringement. If, at any time, Licensor
becomes, or in the opinion of Licensor may become, the subject of a claim of infringement with respect to the Licensed Marks, Licensor may, at its option (i) procure for Licensee the right to continue using the Licensed Marks; or
(ii) terminate this Agreement. 
 7.3 Automatic Termination 

(a) In the event that Licensee dissolves or liquidates or ceases to engage in its business, files a petition in bankruptcy, is
adjudicated a bankrupt or files a petition or otherwise seeks relief under or pursuant to any bankruptcy, insolvency or reorganization statute or proceeding, or if a petition in bankruptcy is filed against it and is not discharged within sixty
(60) days thereafter or if Licensee makes an assignment for the benefit of its creditors or if a custodian, receiver or trustee is appointed for it or for a substantial portion of its business or assets and such appointment is not discharged
within sixty (60) days thereafter (hereinafter individually and/or collectively referred to as “Bankruptcy or Related Proceedings”), then this Agreement will terminate automatically. In the event of Licensee’s Bankruptcy
or Related Proceedings, Licensor and/or its custodian, receiver, or trustee retains the right to reject and terminate this Agreement in its entirety. 

(b) In the event Licensee, in its sole discretion, ceases to use the Licensed Marks with intent not to resume such use, the license
granted under this Agreement will terminate following receipt of written notice from Licensee without any penalty, payment or other form of remuneration from one party to the other. 

7.4 Effect of Termination. In the event of any termination of this Agreement under any circumstance, Licensee shall, subject to the
following sentence, discontinue using the Licensed Marks. In the event of such termination under any circumstance and notwithstanding any other term or condition set out in this Agreement, Licensee shall sell off or exhaust its inventory of any
Medical Products and any other materials or matter that bear any of the Licensed Marks within six (6) months, and thereafter will cease and forever desist from all use of the Licensed Marks and shall not use any mark, designation or design
confusingly similar to any of the Licensed Marks, including any mark that begins with or includes “KIM” anywhere in the world. Nothing herein, however, shall bar or prohibit Licensee after such six-month period from servicing any Medical
Products bearing the Licensed Marks that were marketed or sold prior to the termination or expiration of this Agreement. 
 7.5
Survival. The provisions of Sections 3.3, 5.1, 5.2, 6.1, 6.2 and 7.4 shall survive termination of this Agreement regardless of the reason for termination. 

  
 - 8 - 

 7.6 Condition Precedent to Agreement. The Parties agree that this Agreement shall be null,
void and of no effect unless and until the transaction contemplated by the Distribution Agreement has been closed and consummated. In the event the parties to the Distribution Agreement conclude that such transaction shall not be consummated, this
Agreement shall be deemed to be terminated and of no further force or effect. 
 8. Miscellaneous 

8.1 Non-assignment/Binding Agreement. Neither this Agreement nor any rights under this Agreement may be assigned or otherwise
transferred by Licensee, in whole or in part, whether voluntarily or by operation of law, including by way of sale of assets, merger or consolidation, or Change of Control without the prior written consent of Licensor, which consent will not be
unreasonably withheld. Notwithstanding the foregoing, Licensee may transfer this Agreement to any entity that owns Licensee, is owned by Licensee, or is under common control with Licensee, provided Licensee gives Licensor at least thirty
(30) days advance written notice of such assignment and the proposed transferee entity represents in writing to Licensor that it shall have the authority and will in fact assume and discharge all obligations of Licensee under this Agreement.
Licensor expressly reserves its unilateral right to assign or transfer its interest in this Agreement, provided Licensor gives Licensee at least thirty (30) days advance written notice of such assignment. Subject to the foregoing, this
Agreement will be binding upon and will inure to the benefit of the parties and their respective successors and assigns. Any assignment in violation of the foregoing will be null and void. 

8.2 Independent Contractors. The relationship of the parties under this Agreement is that of independent contractors. Neither party
will be deemed to be an employee, agent, partner, or legal representative of the other for any purpose and neither will have any right, power or authority to create any obligation or responsibility on behalf of the other. Nothing herein shall be
construed as creating any joint venture or other form of joint enterprise between the parties. 
 8.3 Notices. Any notice required or
permitted under the terms of this Agreement or required by law must be in writing and must be: (a) delivered in person; (b) sent by first class registered mail; or (c) sent by overnight courier, in each case properly posted and fully
prepaid to the appropriate address set forth below: 
  

			
	If to Licensor:	  	Kimberly-Clark Worldwide, Inc.
		  	2300 Winchester Road
		  	Neenah, Wisconsin 54956
		
		  	Attention: General Counsel; and

  
 - 9 - 

			
	If to Licensee:	  	Avent, Inc.
		  	5450 Windward Parkway, Suite 100 South
		  	Alpharetta, Georgia 30004
		
		  	Attention: General Counsel

 8.4 Change of Address. Either party may change its address for notice by providing notice to the other
party given in accordance with this Section. Notices will be considered to have been given at the time of actual delivery in person, seven business days after deposit in the mail as set forth above, or three business day after delivery to an
overnight air courier service. 
 8.5 Force Majeure. Neither party will be liable to the other party on account of any loss or damage
resulting from any delay or failure to perform all or any part of this Agreement if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control and without negligence of the party allegedly delaying or
failing to perform. Such events, occurrences, or causes will include, without limitation, acts of God, strikes, lockouts, riots, acts of war, acts of terrorism, earthquake, fire and explosions, but the inability to meet financial obligations is
expressly excluded. 
 8.6 Waiver. Any waiver of the provisions of this Agreement or of a party’s rights or remedies under this
Agreement must be in writing to be effective and signed by the party being charged with waiver. Failure, neglect, or delay by a party to enforce the provisions of this Agreement or its rights or remedies at any time, will not be construed as a
waiver of such party’s rights under this Agreement and will not in any way affect the validity of the whole or any part of this Agreement or prejudice such party’s right to take subsequent action. No exercise or enforcement by either party
of any right or remedy under this Agreement will preclude the enforcement by such party of any other right or remedy under this Agreement or that such party is entitled by law to enforce. 

8.7 Severability. If any of the terms or conditions of this Agreement are declared void, invalid, unlawful or unenforceable by any
judicial or administrative authority having proper jurisdiction over the parties and after all appeals have been exhausted, this declaration shall not, in and of itself, nullify the remaining provisions of this Agreement, which shall remain in force
and effect unless the severing of such term, condition or provision adversely and materially affects the original intent of the parties or the validity of the Licensed Marks; in which event, this Agreement may terminate on sixty (60) days
written notice from one party to the other, provided that the parties have first made reasonable, good faith efforts to reach agreement on modifying such term or condition to fulfill as closely as possible the original intent and purpose thereof.

 8.8 Integration. This Agreement contains the entire agreement of the parties with respect to the subject matter of this Agreement
and supersedes all previous communications, representations, understandings and agreements, either oral or written, between the parties with respect to said subject matter. No terms, provisions or conditions of any purchase order, acknowledgement or
other business form that either party may use in connection 

  
 - 10 - 

 
with the transactions contemplated by this Agreement will have any effect on the rights, duties or obligations of the parties under, or otherwise modify, this Agreement, regardless of any failure
of a receiving party to object to such terms, provisions or conditions. This Agreement may not be amended, except by a writing signed by both parties. 

8.9 Choice of Law and Forum. This Agreement shall be governed by and construed and enforced in accordance with the federal trademark
laws of the United States of America as to trademark issues and the substantive laws of the State of Delaware, as though all acts and omissions related hereto occurred in Delaware, as to contract formation, interpretation and construction. The
Parties hereby irrevocably submit to the non-exclusive jurisdiction of the state and federal courts located in the State of Delaware, and each party hereby irrevocably agrees that all disputes, controversies or claims may be heard and determined in
the state and federal courts located in Wilmington, Delaware. The Parties hereby irrevocably waive, to the fullest extent permitted by applicable law, any objection which they may now or hereafter have to the laying of venue of any such dispute
brought in such court or any defense of inconvenient forum for the maintenance of such dispute. Each of the Parties hereto agrees that a judgment in any such dispute may be enforced in other jurisdictions by suit on the judgment or in any other
manner provided by law. 
 8.10 Interpretation. For purposes of interpreting this Agreement, whenever the context requires, the
singular number will include the plural, and vice versa; the masculine gender will include the feminine and neuter genders; the feminine gender will include the masculine and neuter genders; and the neuter gender will include the masculine and
feminine genders. Any rule of construction to the effect that ambiguities are to be resolved against the drafting party will not be applied in the construction or interpretation of this Agreement. As used in this Agreement, the words
“include” and “including” and variations thereof, will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words “without limitation.” Any reference herein to “the parties”
means the entities that are parties to this agreement; any reference to a “third party” means a person or an entity that is not a party to this Agreement. 

8.11 Counterparts. This Agreement may be executed in counterparts, each of which so executed will be deemed to be an original and such
counterparts together will constitute one and the same agreement. A facsimile, digital or .pdf signature shall be deemed an original. 

  
 - 11 - 

 IN WITNESS WHEREOF, the parties have executed
this Agreement as of the Effective Date. 
  

									
	KIMBERLY-CLARK WORLDWIDE, INC.	 		 	AVENT, INC.
	 (LICENSOR):
	 		 	 (LICENSEE):

					
	By:	 	  
	 		 	By:	 	  

	Name:	 	  
	 		 	Name:	 	  

	Title:	 	  
	 		 	Title:	 	  

  
 - 12 - 

 EXHIBIT A 

ROYALTIES 
 A. The license
granted in this Agreement shall bear royalties at the rate of three-fourths of one percent (0.75%), payable each calendar quarter during the term of this Agreement, commencing on the Effective Date. 

B. Licensee shall remit to Licensor, within thirty (30) days after the close of each calendar quarter, an accounting of all royalties due
to Licensor, accompanied by payment of such royalties in U.S. dollars. The royalties shall be calculated by multiplying the royalty rate set forth in paragraph A above by the total sales by Licensee of Medical Products during the preceding calendar
quarter, exclusive of taxes and less returns during such period. Licensee shall report such royalties on the form prescribed by Licensor, which shall identify all Medical Products and state the volume and total sales for each Licensed Product with
specificity. 
 C. Licensee shall not be obligated to pay royalties to Licensor based on any sales by Licensee of any Medical Products that
were in Licensor’s inventory as of the Effective Date and are transferred to Licensee. Licensor and Licensee shall agree, in writing, as to the value of such inventory, and Licensee may deduct from its royalty payments to Licensor any royalties
that would otherwise be payable to Licensor based on the sales of such inventory by Licensee. Licensee shall report all such sales to Licensor in Licensee’s accountings in accordance with paragraph B above, and may make such deduction(s) either
as one or more lump-sum deduction(s) from its initial royalty payment(s) or on a rolling basis, as such inventory is sold by Licensee. 
 D.
Licensee shall keep complete and accurate books and records relating to Licensee’s sales of Medical Products, and Licensor shall have the right, upon reasonable notice to Licensee but no more frequently than once every two (2) years, to
have an independent certified public accountant of Licensor’s choice to audit such books and records at Licensor’s expense. If any such audit finds that Licensee has under-reported or underpaid the royalties due to Licensor under this
Agreement, Licensee shall remit to Licensor all unpaid royalties within thirty (30) days after the receipt by Licensee of the report of the audit. If any such audit finds that Licensee has under-reported or underpaid royalties by more than five
percent (5%), Licensee shall, in addition to remitting all unpaid royalties, also reimburse Licensor for all costs incurred by Licensor in connection with such audit, including all fees and expenses of the accountant that conducted the audit. 

EXHIBIT A 

 APPENDIX A 

MARKS AND REGISTRATIONS 
 I. MARKS

 The marks, whether registered or not, that (a) are used both on or in connection with Medical Products marketed to the Health Care
Market and other products; and (b) are not the subject of any other license agreement between Licensor and Licensee, including but not limited to: 

KIMBERLY-CLARK 
 K-C 

 
 

                                    
                     
 KIMBERLY-CLARK
KIMPACK 
 KIMCARE 
 KIMFLEX

 KIMLIFE 
 KIMPACK 

KIMSMART 
 KIMTHERM 

KIMTRACH 
 KIMVENT 

the distinctive configurations of any such Medical Products 

the trade dress used for any such Medical Products 

APPENDIX A 

  
 - 1 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]